1. The company saw net income of $24.5 million, up 133.9 percent from the same period a year prior.
2. The company acquired Bioness for $45 million on March 30.
3. The company updated its revenue guidance for 2021, driven by first-quarter results. Bioventus now expects full-year revenue of $394 million to $406 million.
4. Bioventus had an EBITDA of $11.1 million, down $3.2 million from the first quarter of 2020 — which their report said was driven by public company costs and higher selling expenses due to better-than-expected sales.
“Bioventus delivered better-than-expected first quarter revenue results, driven primarily by accelerating U.S. sales growth trends as we moved through the quarter, culminating with nearly 30 percent year-over-year growth in March,” said Ken Reali, CEO of Bioventu
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
